新型冠状病毒肺炎疾病实验室标志物的应用研究进展
Research Progress in the Application of Laboratory Markers for COVID-19
DOI: 10.12677/ACM.2022.1281073, PDF,   
作者: 潘晓娟：浙江大学医学院附属邵逸夫医院检验科，浙江 杭州
关键词: 新型冠状病毒；诊断治疗；实验室标志物；SARS-CoV-2； Diagnosis and Treatment； Laboratory Markers
摘要: 新型冠状病毒传播能力强，可通过人传人、物传人等多种途径传播，传播速度较快，全面防控较困难，部分感染者由无症状感染转为确诊患者，临床表现多样，对患者机体造成严重的后果。及时通过实验室检测以及一些标志物的应用使得临床对新型冠状病毒肺炎患者尽早干预，精准治疗。该文就新型冠状病毒肺炎疾病进展相关的实验室标志物进行综述，为临床诊治提供参考及帮助。
Abstract: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has a strong transmission ca-pacity and can be transmitted through a variety of ways, such as person-to-person or ob-ject-to-person transmission. The transmission speed is relatively fast and comprehensive preven-tion and control is difficult. Some of the infected persons started with asymptomatic infection and turned to confirmed patients with various clinical manifestations, causing serious consequences to the body. Timely laboratory testing and the application of some markers could enable early inter-vention and precise treatment for Corona Virus Disease 2019 (COVID-19) patients. In this review, laboratory markers related to COVID-19 disease progression were reviewed to provide reference and help for clinical diagnosis and treatment.
文章引用：潘晓娟. 新型冠状病毒肺炎疾病实验室标志物的应用研究进展[J]. 临床医学进展, 2022, 12(8): 7429-7432. https://doi.org/10.12677/ACM.2022.1281073

参考文献

[1] 国家卫生健康委员会办公厅. 新型冠状病毒肺炎诊疗方案(试行第九版) [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml, 2022-03-15.
[2] Tajbakhsh, A., Gheibi Hayat, S.M., Taghizadeh, H., et al. (2021) Covid-19 and Cardiac Injury: Clini-cal Manifestations, Biomarkers, Mechanisms, Diagnosis, Treatment, and Follow Up. Expert Review of Anti-Infective Therapy, 19, 345-357. [Google Scholar] [CrossRef] [PubMed]
[3] Guo, T., Fan, Y.Z., Chen, M., et al. (2020) Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 5, 811-818. [Google Scholar] [CrossRef] [PubMed]
[4] 尹亮, 甘露. 新型冠状病毒肺炎与心肌损伤的研究进展[J]. 河北医科大学学报, 2021, 42(4): 487-491. [Google Scholar] [CrossRef] 
[5] 郑雨桐, 闫美田, 王兰, 等. 新型冠状病毒肺炎患者并发心肌损伤的实验室及临床相关研究[J]. 现代检验医学杂志, 2021, 36(1): 85-91. [Google Scholar] [CrossRef] 
[6] 章晋辉, 徐留胜, 郭雨萌, 等. 新型冠状病毒肺炎患者临床特征与心肌损伤标志物的变化[J]. 医学新知, 2021, 31(5): 342-349. [Google Scholar] [CrossRef] 
[7] 池锐彬, 罗建锋, 江嘉文, 等. 新型冠状病毒肺炎患者急性肾损伤的临床特征及早期诊断[J].肾脏病与透析肾移植杂志, 2020, 29(5): 408-412. [Google Scholar] [CrossRef] 
[8] 林柳, 胡凯元, 邵欣宁, 等. 新型冠状病毒肺炎患者并发急性肾损伤的临床分析[J]. 实用医学杂志, 2020, 36(7): 835-838. [Google Scholar] [CrossRef] 
[9] 郭凤霞, 赖勋息, 王亚萍, 等. 新型冠状病毒肺炎患者合并肝功能损伤临床特征[J]. 中华实验和临床病毒学杂志, 2021, 35(6): 675-679. [Google Scholar] [CrossRef] 
[10] 陈柯颖, 连江山, 许珊, 等. 新型冠状病毒肺炎85例患者肝功能损伤研究[J]. 中华临床感染病杂志, 2020, 13(4): 291-294. [Google Scholar] [CrossRef] 
[11] 朱晖, 李晨芳, 余波, 等. 365例COVID-19患者血常规分析[J]. 检验医学与临床, 2021, 18(1): 44-47. [Google Scholar] [CrossRef] 
[12] Zheng, Y., Xu, H., Yang, M., et al. (2020) Epidemio-logical Characteristics and Clinical Features of 32 Critical and 67 Noncritical Cases of COVID-19 in Chengdu. Journal of Clinical Virology, 127, Article ID: 104366. [Google Scholar] [CrossRef] [PubMed]
[13] 朱传新, 周玉平, 何艳, 等. NLR、CRP、PCT、DD、NT-proBNP在重症COVID-19中的诊断价值[J]. 检验医学, 2021, 36(2): 190-193. [Google Scholar] [CrossRef] 
[14] 肖武强, 苏立杰, 杨璐瑜, 等. 纤维蛋白原联合D-二聚体对新型冠状病毒肺炎预后的预测价值[J]. 临床肺科杂志, 2021, 26(5): 658-662. [Google Scholar] [CrossRef] 
[15] Rostami, M. and Mansouritorghabeh, H. (2020) D-Dimer Level in Covid-19 Infection: A Systematic Review. Expert Review of Hematology, 13, 1265-1275. [Google Scholar] [CrossRef] [PubMed]

为你推荐